BRITANNIA LIFE SCIENCES
Britannia Life Sciences Inc. engages in the product testing, safety assessment, and manufacturing services in the United Kingdom and internationally. It serves cosmetics, consumer packaged and household goods, and nutraceutical industries. The company is headquartered in Toronto, Canada.
Market Cap & Net Worth: BRITANNIA LIFE SCIENCES (L020)
BRITANNIA LIFE SCIENCES (F:L020) has a market capitalization of $7.58 Million (€7.38 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #31461 globally and #3498 in its home market, demonstrating a -4.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BRITANNIA LIFE SCIENCES's stock price €0.05 by its total outstanding shares 162254339 (162.25 Million).
BRITANNIA LIFE SCIENCES Market Cap History: 2022 to 2026
BRITANNIA LIFE SCIENCES's market capitalization history from 2022 to 2026. Data shows change from $5.01 Million to $7.58 Million (-23.67% CAGR).
BRITANNIA LIFE SCIENCES Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BRITANNIA LIFE SCIENCES's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of L020 by Market Capitalization
Companies near BRITANNIA LIFE SCIENCES in the global market cap rankings as of March 19, 2026.
Key companies related to BRITANNIA LIFE SCIENCES by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BRITANNIA LIFE SCIENCES Historical Marketcap From 2022 to 2026
Between 2022 and today, BRITANNIA LIFE SCIENCES's market cap moved from $5.01 Million to $ 7.58 Million, with a yearly change of -23.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.58 Million | +10.98% |
| 2025 | €6.83 Million | +6.49% |
| 2024 | €6.41 Million | +16.67% |
| 2023 | €5.50 Million | +9.63% |
| 2022 | €5.01 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BRITANNIA LIFE SCIENCES was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.58 Million USD |
| MoneyControl | $7.58 Million USD |
| MarketWatch | $7.58 Million USD |
| marketcap.company | $7.58 Million USD |
| Reuters | $7.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.